Timothy Rolph's most recent trade in Akero Therapeutics Inc was a trade of 12,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2025 | 12,500 | 19,933 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.09 per share. | 07 Jul 2025 | 12,500 | 179,624 (0%) | 0% | 21.1 | 263,625 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 50.93 per share. | 07 Jul 2025 | 10,634 | 168,990 (0%) | 0% | 50.9 | 541,611 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 52.00 per share. | 07 Jul 2025 | 1,825 | 167,165 (0%) | 0% | 52.0 | 94,893 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 52.61 per share. | 07 Jul 2025 | 41 | 167,124 (0%) | 0% | 52.6 | 2,157 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 23.87 per share. | 30 Jun 2025 | 890 | 167,124 (0%) | 0% | 23.9 | 21,243 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 54.84 per share. | 18 Jun 2025 | 1,129 | 166,234 (0%) | 0% | 54.8 | 61,914 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 54.00 per share. | 10 Jun 2025 | 2,358 | 167,363 (0%) | 0% | 54.0 | 127,323 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.04 per share. | 05 Jun 2025 | 25,000 | 169,721 (0%) | 0% | 55.0 | 1,376,000 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2025 | 24,611 | 32,433 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.09 per share. | 05 Jun 2025 | 24,611 | 194,332 (0%) | 0% | 21.1 | 519,046 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 05 Jun 2025 | 12,500 | 182,221 (0%) | 0% | 21.1 | 263,750 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2025 | 12,500 | 389 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 53.37 per share. | 05 Jun 2025 | 9,350 | 172,871 (0%) | 0% | 53.4 | 499,038 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 53.84 per share. | 05 Jun 2025 | 3,150 | 169,721 (0%) | 0% | 53.8 | 169,596 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2025 | 389 | 0 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 05 Jun 2025 | 389 | 194,721 (0%) | 0% | 21.1 | 8,208 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 06 May 2025 | 12,500 | 182,221 (0%) | 0% | 21.1 | 263,750 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2025 | 12,500 | 12,889 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 43.87 per share. | 06 May 2025 | 8,650 | 170,021 (0%) | 0% | 43.9 | 379,476 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 42.26 per share. | 06 May 2025 | 3,550 | 178,671 (0%) | 0% | 42.3 | 150,037 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 06 May 2025 | 300 | 169,721 (0%) | 0% | 44.5 | 13,351 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 24 Apr 2025 | 6,250 | 175,971 (0%) | 0% | 21.1 | 131,875 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.03 per share. | 24 Apr 2025 | 6,250 | 169,721 (0%) | 0% | 41.0 | 256,438 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2025 | 3,684 | 25,389 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Apr 2025 | 2,566 | 26,152 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 07 Apr 2025 | 6,250 | 175,971 (0%) | 0% | 21.1 | 131,875 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 6,250 | 28,718 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.05 per share. | 07 Apr 2025 | 3,750 | 170,021 (0%) | 0% | 36.1 | 135,203 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.36 per share. | 07 Apr 2025 | 2,200 | 173,771 (0%) | 0% | 35.4 | 77,783 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.92 per share. | 07 Apr 2025 | 200 | 169,721 (0%) | 0% | 37.9 | 7,583 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.93 per share. | 07 Apr 2025 | 100 | 169,921 (0%) | 0% | 36.9 | 3,693 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 44.88 per share. | 12 Mar 2025 | 516 | 169,721 (0%) | 0% | 44.9 | 23,158 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 12,500 | 34,968 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 05 Mar 2025 | 12,500 | 182,737 (0%) | 0% | 21.1 | 263,750 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 44.40 per share. | 05 Mar 2025 | 9,338 | 173,399 (0%) | 0% | 44.4 | 414,617 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 44.90 per share. | 05 Mar 2025 | 3,162 | 170,237 (0%) | 0% | 44.9 | 141,974 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 05 Feb 2025 | 18,750 | 188,987 (0%) | 0% | 21.1 | 395,625 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 18,750 | 47,468 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 56.32 per share. | 05 Feb 2025 | 12,847 | 176,140 (0%) | 0% | 56.3 | 723,607 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 56.92 per share. | 05 Feb 2025 | 5,903 | 170,237 (0%) | 0% | 56.9 | 336,022 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 16,264 | 66,218 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.10 per share. | 27 Jan 2025 | 16,264 | 201,487 (0%) | 0% | 21.1 | 343,170 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 14,986 | 119,969 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.87 per share. | 27 Jan 2025 | 14,986 | 185,223 (0%) | 0% | 19.9 | 297,772 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 54.76 per share. | 27 Jan 2025 | 13,812 | 187,675 (0%) | 0% | 54.8 | 756,345 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 56.97 per share. | 27 Jan 2025 | 12,379 | 170,237 (0%) | 0% | 57.0 | 705,232 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.62 per share. | 27 Jan 2025 | 5,059 | 182,616 (0%) | 0% | 55.6 | 281,382 | Common Stock |
| Akero Therapeutics Inc | Rolph Timothy | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Dec 2024 | 14,100 | 184,237 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Rolph Timothy | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Rolph Timothy | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2024 | 20,000 | 198,337 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.10 per share. | 16 Dec 2024 | 3,800 | 178,337 (0%) | 0% | 31.1 | 118,172 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.87 per share. | 16 Dec 2024 | 3,800 | 182,137 (0%) | 0% | 19.9 | 75,506 | Common Stock |
| Akero Therapeutics Inc | Rolph Timothy | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 3,800 | 134,955 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 2,450 | 138,755 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Rolph Timothy | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.03 per share. | 10 Dec 2024 | 2,450 | 178,337 (0%) | 0% | 31.0 | 76,024 | Common Stock |
| Akero Therapeutics Inc | Rolph Timothy | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.87 per share. | 10 Dec 2024 | 2,450 | 180,787 (0%) | 0% | 19.9 | 48,682 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.79 per share. | 10 Dec 2024 | 2,368 | 178,337 (0%) | 0% | 30.8 | 72,911 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.18 per share. | 10 Sep 2024 | 537 | 180,705 (0%) | 0% | 26.2 | 14,059 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 19.94 per share. | 28 Jun 2024 | 1,064 | 181,242 (0%) | 0% | 19.9 | 21,217 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.64 per share. | 11 Jun 2024 | 2,380 | 180,178 (0%) | 0% | 22.6 | 53,886 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.33 per share. | 13 Mar 2024 | 619 | 182,558 (0%) | 0% | 28.3 | 17,536 | Common Stock |
| Akero Therapeutics Inc | Rolph Timothy | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.76 per share. | 14 Dec 2023 | 514 | 182,672 (0%) | 0% | 20.8 | 10,671 | Common Stock |
| Akero Therapeutics Inc | Rolph Timothy | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 146,237 | 146,237 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Rolph Timothy | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2023 | 32,497 | 183,186 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 54.58 per share. | 16 Jun 2023 | 49,325 | 180,095 (0%) | 0% | 54.6 | 2,691,912 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2023 | 40,000 | 2,796 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.61 per share. | 16 Jun 2023 | 40,000 | 229,420 (0%) | 0% | 0.6 | 24,400 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.08 per share. | 16 Jun 2023 | 27,462 | 152,633 (0%) | 0% | 55.1 | 1,512,607 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 56.30 per share. | 16 Jun 2023 | 1,413 | 151,220 (0%) | 0% | 56.3 | 79,547 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 55.16 per share. | 13 Jun 2023 | 509 | 189,420 (0%) | 0% | 55.2 | 28,076 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.47 per share. | 10 Mar 2023 | 603 | 189,929 (0%) | 0% | 43.5 | 26,212 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 51.38 per share. | 28 Dec 2022 | 12,293 | 190,532 (0%) | 0% | 51.4 | 631,571 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 50.55 per share. | 28 Dec 2022 | 8,023 | 202,825 (0%) | 0% | 50.5 | 405,547 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2022 | 7,816 | 66,267 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.35 per share. | 28 Dec 2022 | 7,816 | 210,848 (0%) | 0% | 28.4 | 221,584 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2022 | 1,700 | 74,083 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 28 Dec 2022 | 1,700 | 203,032 (0%) | 0% | 50.0 | 85,006 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.35 per share. | 28 Dec 2022 | 1,700 | 204,732 (0%) | 0% | 28.4 | 48,195 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 29,073 | 87,221 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 86,379 | 86,379 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2022 | 19,195 | 203,032 (0%) | 0% | 0 | Common Stock | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 45.45 per share. | 15 Nov 2022 | 3,847 | 183,937 (0%) | 0% | 45.5 | 174,859 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 45.04 per share. | 15 Nov 2022 | 3,138 | 187,784 (0%) | 0% | 45.0 | 141,343 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 46.05 per share. | 15 Nov 2022 | 100 | 183,837 (0%) | 0% | 46.1 | 4,605 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 45.09 per share. | 25 Oct 2022 | 10,653 | 195,684 (0%) | 0% | 45.1 | 480,349 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.36 per share. | 25 Oct 2022 | 8,203 | 204,540 (0%) | 0% | 6.4 | 52,171 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2022 | 8,203 | 48,225 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 45.03 per share. | 25 Oct 2022 | 4,762 | 190,922 (0%) | 0% | 45.0 | 214,433 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.35 per share. | 25 Oct 2022 | 1,797 | 206,337 (0%) | 0% | 28.4 | 50,945 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2022 | 1,797 | 75,783 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.29 per share. | 06 Oct 2022 | 22,500 | 186,337 (0%) | 0% | 39.3 | 884,025 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.09 per share. | 06 Oct 2022 | 10,000 | 208,837 (0%) | 0% | 21.1 | 210,900 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2022 | 10,000 | 61,328 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 34.06 per share. | 30 Sep 2022 | 22,500 | 198,837 (0%) | 0% | 34.1 | 766,350 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 31.38 per share. | 30 Sep 2022 | 22,500 | 221,337 (0%) | 0% | 31.4 | 706,050 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.09 per share. | 30 Sep 2022 | 13,672 | 243,837 (0%) | 0% | 21.1 | 288,342 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 13,672 | 71,328 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2022 | 6,328 | 66,428 | - | - | Stock Option (Right to Buy) | |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.36 per share. | 30 Sep 2022 | 6,328 | 230,165 (0%) | 0% | 6.4 | 40,246 | Common Stock |
| Akero Therapeutics Inc | Timothy Rolph | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.18 per share. | 13 Sep 2022 | 22,500 | 233,837 (0%) | 0% | 29.2 | 656,550 | Common Stock |